Ocugen Heads Toward Phase III In Dry Eye With Potential Benefits Over Older Drugs

Biotech hopes to counter established Restasis and Xiidra in dry eye with a combination of two approved ophthalmology eye drops, offering quicker onset of action, tolerability and strong efficacy.